Updates in HER2+ Early and Metastatic Breast Cancer

Virginia Borges, MD, explains how common HER2+ early breast cancer is and the goals of treatment for patients.

A review of the standard of care regimens for the preoperative or neoadjuvant treatment of HER2+ early breast cancer.

Debu Tripathy, MD, details when he utilizes a treatment de-escalation approach in his patients with HER2+ early breast cancer.

The panel shares the factors that influence whether they recommend a subcutaneous or intravenous formulation of pertuzumab/trastuzumab in addition to chemotherapy.

A look at how patient response to neoadjuvant treatment for HER2+ early breast cancer informs adjuvant treatment selection.

The panel explains their clinical experiences with using the antibody-drug conjugate (ADC) ado-trastuzumab emtansine (T-DM1) to treat HER2+ early breast cancer.

A review of recently reported data on the use of adjuvant pertuzumab/trastuzumab for the treatment of HER2+ early breast cancer, including data from the APHINITY and PHranceSCa trials.

Joyce O’Shaughnessy, MD, starts a conversation on which patients with HER2+ early breast cancer are the best candidates for extended adjuvant neratinib therapy.

The panel highlights recent data updates in adjuvant treatment of HER2+ early breast cancer, including longer-term follow-up data from the APT and ATEMPT trials.

A focused discussion on available options for the first-line treatment of HER2+ metastatic breast cancer (mBC), with reference to data from the CLEOPATRA trial.

Maryam Lustberg, MD, MPH introduces the standard of care regimens for the second-line treatment of HER2+ metastatic breast cancer, followed by a discussion of recent data on the ADC trastuzumab deruxtecan (T-DXd).

Dr Debu Tripathy explains the treatment options for patients with HER2+ metastatic breast cancer in the third-line and later-line settings, including combination tucatinib/trastuzumab/capecitabine.

The panel discusses the management of patients with HER2+ mBC with asymptomatic brain mets and shares their thoughts on the use of surveillance brain MRI in this setting.

The panel highlights emerging data from SABCS 2022 on investigational agents being explored for HER2+ mBC treatment.

The panel closes their discussion by summarizing the most exciting recent advances in HER2+ breast cancer, the future of treatment, and unmet needs that must be addressed.